Starpax Biopharma introduces its cancer treatment platform, Starpax Magnetodrones and PolarTrak to fight against cancer

Starpax Biopharma Inc. integrates biochemistry, microbiology, electromagnetism engineering, and artificial intelligence to revolutionize cancer treatment. Their recent innovation, the Starpax cancer treatment platform, boasts a 100% remission rate and no side effects in preclinical trials, targeting all solid tumors, which constitute 90% of cancers and 89% of related deaths.

The technology tackles a persistent challenge in cancer therapy: ineffective drug delivery to tumors despite advances in chemotherapy and immunotherapy. Most tumors receive inadequate drug exposure due to dysfunctional blood vessels, with systemic chemotherapy delivering just 1% of the drug to the tumor.

Key components include Magnetodrones, non-pathogenic bacteria carrying anticancer drugs and responsive to magnetic fields, injected directly into tumors for precise drug delivery. Complementing this is PolarTrak, a device generating magnetic fields to confine Magnetodrones within tumors, ensuring comprehensive coverage, even in hypoxic areas harboring cancer stem cells.

Founded with two patents in 2017, Starpax now holds 57 patents, aiming to start clinical trials by 2025 after securing a $24 million Regulation A+ capital raise.